Author

D. Vazquez-Blomquist

Listed by name: these papers carry no ORCID for this author, so different people with the same name may be mixed together.

Biology Disciplines

Click to filter author papers

Cancer Biology· 4

Signature Assays, Organisms & Methods

Click to filter · or open tag

Organism:human· 4 Research Focus:cell type annotation· 3 Approach:experimental assay· 3 Assay:bulk RNA-seq· 2 Research Focus:differential expression· 2 Assay:proteomics· 2 Approach:statistical model· 2 Research Focus:cell signaling & trafficking· 1

Frequent Co-Authors

A. C. Ramon· 2 shared D. Palenzuela· 2 shared G. V. Perez· 2 shared J. R. Wisniewski· 2 shared L. J. Gonzalez· 2 shared M. Rosales· 2 shared S. E. Perea· 2 shared V. Besada· 2 shared

Activity by Year

2021-2023 · peak 2/yr

Co-Author Collaboration Network

10 top collaborators · 41 mutual co-author links

Click any collaborator node to inspect or filter shared papers

Focal author (center)Selected co-authorORCID co-authorUnlinked name

Curved chords = mutual co-authorship

2 shared papersCancer Biology

A. C. Ramon

Mutual co-authors in cluster

Author profile →

4 papers

Recent·Most cited

Gene Expression Profiling Unveils the Temporal Dynamics of CIGB-300-Regulated Transcriptome in AML Cells

D. Vazquez-Blomquist, A. C. Ramon, M. Rosales, G. V. Perez, A. Rosales, D. Palenzuela, Y. Perera, S. E. Perea

This study uses microarray profiling to analyze the time-dependent gene expression changes in AML cell lines treated with CIGB-300, identifying modulated genes and pathways involved in apoptosis, cell cycle, and inflammation.

bioRxiv · Mar 6, 2023 · PreprintCancer Biology

Proteomics and phosphoproteomics profiling of the co-formulation of type I and II interferons, HeberFERON, in the glioblastoma-derived cell line U-87 MG

D. Vazquez-Blomquist, A. Hardy-Sosa, S. C. Baez, V. Besada, S. Palomares, O. Guirola, Y. Ramos, J. R. Wisniewski, L. J. Gonzalez, I. Bello-Rivero

This study uses proteomic and phosphoproteomic analyses to investigate the effects of HeberFERON on U-87 MG glioblastoma cells, identifying key pathways and phosphosites involved in antiproliferative responses.

bioRxiv · Oct 3, 2022 · PreprintCancer Biology

HeberFERON distinctively targets Cell Cycle in the glioblastoma-derived cell line U-87MG.

J. Miranda, D. Vazquez-Blomquist, R. Bringas, J. Fernandez-de-Cossio, D. Palenzuela, L. I. Novoa, B.-R. J. Iraldo

This paper identifies molecular mechanisms of HeberFERON's distinct effect on the glioblastoma cell line U-87MG, showing its unique impact on the cell cycle.

bioRxiv · Sep 22, 2022 · PreprintCancer Biology

Targeting of Protein Kinase CK2 in Acute Myeloid Leukemia Cells Using the Clinical-Grade Synthetic-Peptide CIGB-300

M. Rosales, G. V. Perez, A. C. Ramon, Y. Cruz, A. Rodriguez-Ulloa, V. Besada, Y. Ramos, D. Vazquez-Blomquist, E. Caballero, D. Aguilar, L. J. Gonzalez, K. Zettl, J. R. Wisniewski, Y. Ke, Y. Perera, S. E. Perea

This study investigates the anti-proliferative and proapoptotic effects of the CK2 inhibitor CIGB-300 on AML cells and identifies its molecular targets.

bioRxiv · May 19, 2021Cancer Biology